CUMBERLAND PHARMACEUTICALS ANNOUNCES NATIONAL CALL TO PRESENT AN UPDATE ON ITS IFETROBAN DMD PROGRAM

Cumberland Pharmaceuticals (Nasdaq: CPIX) will hold a national webcast and conference call on October 26 to update its ifetroban DMD program.

Rhea-AI Summary

Cumberland Pharmaceuticals (Nasdaq: CPIX) will hold a national webcast and conference call on October 26 to update its ifetroban DMD program. The event begins at 4:30 p.m. Eastern Time and will cover the product candidate's development as a potential treatment for cardiomyopathy associated with Duchenne muscular dystrophy (DMD), a condition affecting the heart muscle.

Webcast participants can view accompanying slides, while the conference call offers audio-only access. A copy of the presentation will be available on Cumberland's Investor Relations website.

Key Terms

cardiomyopathy, duchenne muscular dystrophy

2 terms

cardiomyopathy medical

"cardiomyopathy associated with Duchenne muscular dystrophy"

A condition that weakens or stiffens the heart muscle, reducing its ability to pump blood effectively; think of the heart as an engine that becomes less powerful or less flexible. For investors, cardiomyopathy matters because it can drive demand for medical treatments, affect healthcare costs, influence the value of companies developing drugs or devices, and trigger regulatory or insurance impacts that change revenues and risks across the healthcare sector.

duchenne muscular dystrophy medical

"cardiomyopathy associated with Duchenne muscular dystrophy"

A rare, inherited condition that progressively weakens muscles, Duchenne muscular dystrophy causes the body’s muscle fibers to break down over time, often leading to severe disability. For investors, it matters because the small, well-defined patient population, high unmet medical need and complex regulatory and pricing dynamics mean successes or failures in clinical trials, approvals, or therapies can have outsized effects on a company’s valuation and future revenue prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NASHVILLE, Tenn., Oct. 19, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, announced today that it will provide an update on its ifetroban product candidate in development as a potential treatment for the cardiomyopathy associated with Duchenne muscular dystrophy ("DMD").

A national webcasting event and conference call will be held on Monday, October 26^th at 4:30 p.m. Eastern Time to provide the update. Participants may join the presentation via webcast, to view the accompanying slides, or by conference call for audio-only access.

Webcast Participation

The link to register for the webcast participation is:
https://edge.media-server.com/mmc/p/e4k38y5q

Call Participation

The link to register for the conference call participation is:
https://register-conf.media-server.com/register/BI5f9f9d5a8fef425b99857a39138a38e9

Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.

Presentation Copy

A copy of the presentation will be available and can be accessed via the Investor Relations page of the Cumberland Pharmaceuticals website at: https://investor.cumberlandpharma.com/events-presentations 

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is an innovation-driven biopharmaceutical company developing new therapies to address significant unmet medical needs and improve patient outcomes.

Cumberland's clinical programs are evaluating ifetroban in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis and Cancer Metastasis.

For more information, please visit www.cumberlandpharma.com

View original content:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-announces-national-call-to-present-an-update-on-its-ifetroban-dmd-program-302913065.html

SOURCE Cumberland Pharmaceuticals Inc.